Aeterna Zentaris to merge with Ceapro.

Aeterna Zentaris, a biopharmaceutical company focused on developing and commercializing pharmaceutical and diagnostic products, agreed to merge with Ceapro, a Canadian biotechnology company involved in the development of proprietary extraction technology. “The transaction provides us with the additional capital and internal capabilities to fully support near-term revenue generating cosmeceutical and nutraceutical product development programs, while achieving Ceapro’s previously stated objective of expanding further into the pharmaceutical space, which we will be able to do via the exciting projects Aeterna has been developing, even as we seek to extract additional value from Ceapro’s core technologies. This is an exciting day for stakeholders of both companies who share a bright future together,” Gilles Gagnon, Ceapro CEO